BioSpace News Archive

Drug Development

Viridian Presents Positive Clinical Data from Ongoing VRDN-001 Phase 1/2 Trial in Active Thyroid Eye Disease (TED) Patients During Late-Breaking Presentations at the American Thyroid Association (ATA) 91st Annual Meeting

Viridian Therapeutics, Inc., a biotechnology company advancing new treatments for patients suffering from serious diseases underserved by current therapies, presented positive proof-of-concept data from the 10 mg/kg cohort in its ongoing Phase 1/2 clinical trial of VRDN-001, an anti-IGF-1R antibody, in patients with active thyroid eye disease.

October 22, 2022
·
8 min read
Drug Development

New Phase 2 TOPAZ Trial Data Indicate Positive Trends in Quality-of-Life Measures Over 24 Months with Apitegromab for Nonambulatory Patients with Types 2 and 3 SMA

Tertiary endpoint data show trends of continuous improvement in activities of daily living, fatigue, and endurance over 24 months These data indicate the potential for sustained improvement in quality-of-life measures for patients with symptomatic SMA and offer further evidence of possible durable effects of apitegromab

October 22, 2022
·
11 min read
Drug Development

Merck’s PREVYMIS™ Demonstrates Efficacy in Phase 3 Study for Prevention of Cytomegalovirus Disease in Adults After Kidney Transplantation

Merck announced today the presentation of findings from a Phase 3 clinical trial that assessed safety and efficacy of PREVYMIS™ compared to valganciclovir for cytomegaloviru prophylaxis in 601 adult kidney transplant recipients at high risk for CMV disease.

October 22, 2022
·
16 min read
BioMidwest

New Real-World Analysis of TEPEZZA® (teprotumumab-trbw) Use Indicates a Small Percentage of People Receive a Second Course of Treatment

Horizon Therapeutics plc announced new data from a real-world analysis of TEPEZZA presented at the 91st Annual Meeting of the ATA.

October 22, 2022
·
6 min read